438 related articles for article (PubMed ID: 23337211)
1. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
Barkun AN; Adam V; Martel M; Bardou M
Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Histamine
Hammond DA; Kathe N; Shah A; Martin BC
Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
[TBL] [Abstract][Full Text] [Related]
3. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding.
Al-Sabah S; Barkun AN; Herba K; Adam V; Fallone C; Mayrand S; Pomier-Layrargues G; Kennedy W; Bardou M
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):418-25. PubMed ID: 18304891
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*.
MacLaren R; Campbell J
Crit Care Med; 2014 Apr; 42(4):809-15. PubMed ID: 24365863
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis.
Barkun AN; Bardou M; Pham CQ; Martel M
Am J Gastroenterol; 2012 Apr; 107(4):507-20; quiz 521. PubMed ID: 22290403
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis for stress ulcer bleeding in the intensive care unit].
Avendaño-Reyes JM; Jaramillo-Ramírez H
Rev Gastroenterol Mex; 2014; 79(1):50-5. PubMed ID: 24629722
[TBL] [Abstract][Full Text] [Related]
9. [Proton pump inhibitor H2 receptor antagonist].
Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
11. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
Scally B; Emberson JR; Spata E; Reith C; Davies K; Halls H; Holland L; Wilson K; Bhala N; Hawkey C; Hochberg M; Hunt R; Laine L; Lanas A; Patrono C; Baigent C
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):231-241. PubMed ID: 29475806
[TBL] [Abstract][Full Text] [Related]
12. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
13. [Bleeding and pneumonia in intensive care unit patients given proton pump inhibitor or histamine-2 receptor antagonist for prevention of stress ulcer: a Meta analysis].
Zhou JF; Wan XY; Huang W; Han LL
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Apr; 22(4):221-5. PubMed ID: 20398466
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
[TBL] [Abstract][Full Text] [Related]
15. Pneumonia prevention in intubated patients given sucralfate versus proton-pump inhibitors and/or histamine II receptor blockers.
Grindlinger GA; Cairo SB; Duperre CB
J Surg Res; 2016 Dec; 206(2):398-404. PubMed ID: 27884335
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
[TBL] [Abstract][Full Text] [Related]
17. A pragmatic assessment of proton pump inhibitors vs. histamine type 2 receptor antagonists on clinically important gastrointestinal bleeding and mortality when used for stress ulcer prophylaxis in the ICU.
Boyd C; Hassig T; MacLaren R
Pharmacotherapy; 2021 Oct; 41(10):820-827. PubMed ID: 34478588
[TBL] [Abstract][Full Text] [Related]
18. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.
Kantorova I; Svoboda P; Scheer P; Doubek J; Rehorkova D; Bosakova H; Ochmann J
Hepatogastroenterology; 2004; 51(57):757-61. PubMed ID: 15143910
[TBL] [Abstract][Full Text] [Related]
19. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
20. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.
Tett SE; Sketris I; Cooke C; van Zanten SV; Barozzi N
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):735-43. PubMed ID: 23559528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
